Domov › Trojnásobne negatívny karcinóm prsníka › Illinois › Chicago
Klinické štúdie Trojnásobne negatívny karcinóm prsníka v meste Chicago, IL
16 štúdií pre Trojnásobne negatívny karcinóm prsníka hľadá účastníkov v zariadeniach v meste Chicago a okolí (do cca 30 míľ). Otvorte štúdiu a zistite, kto sa môže zapojiť a ako kontaktovať tím.
Oficiálny text štúdie (anglicky)
Hľadáte účastníkov do štúdie? Zvýraznite ju na začiatku tejto stránky – $99 na 30 dní →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Prebieha náborFáza 1
- University of Chicago Hospital, Chicago
PRE-ISPY Phase I/II Oncology Platform Program
Prebieha náborFáza 1/2
- The University of Chicago Medicine Comprehensive Cancer Center, Chicago
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Prebieha náborFáza 3
- University of Illinois Cancer Center ( Site 0044), Chicago
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Prebieha náborFáza 1
- Northwestern University Feinberg School of Medicine, Chicago
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Prebieha náborFáza 3
- Northwestern Medicine, Chicago
- Rush University Medical Center, Chicago
- University of Chicago Medical Center, Chicago
SMP-3124LP in Adults With Advanced Solid Tumors
Prebieha náborFáza 1/2
- Northwestern Medicine Cancer Center, Chicago
- The University of Chicago, Chicago
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Prebieha náborFáza 2/3
- Local Institution - 0280, Chicago
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Prebieha náborFáza 1/2
- Northwestern University, Chicago
A Study of LY4175408 in Participants With Advanced Cancer
Prebieha náborFáza 1
- The University of Chicago Medical Center (UCMC), Chicago
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Prebieha náborFáza 1
- University of Illinois Hospital and Health Sciences System /ID# 251750, Chicago
- University of Chicago Medical Center /ID# 276271, Chicago
Study of XB010 in Subjects With Solid Tumors
Prebieha náborFáza 1
- University of Chicago Medical Center, Chicago
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Prebieha náborFáza 1/2
- Northwestern Memorial Hospital, Chicago
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Prebieha náborFáza 2
- University of Chicago, Chicago
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
Prebieha náborFáza 2
- University of Chicago Medical Center, Chicago
A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
Prebieha náborFáza 1
- UChicago Medicine Comprehensive Cancer Center, Chicago
A Study of NX-1607 in Adults With Advanced Malignancies
Prebieha náborFáza 1
- University of Chicago, Chicago
Štúdie Trojnásobne negatívny karcinóm prsníka v iných mestách
- Houston, TX42 štúdií
- New York City, NY31 štúdií
- Nashville, TN28 štúdií
- Los Angeles, CA27 štúdií
- Boston, MA26 štúdií
- San Antonio, TX23 štúdií
- St. Louis, MO21 štúdií
- Arlington, VA20 štúdií
- Atlanta, GA20 štúdií
- Dallas, TX18 štúdií
- Columbus, OH16 štúdií
- Grand Rapids, MI15 štúdií
Iné štúdie v Chicago
- Nemalobunkový karcinóm pľúc61 štúdií
- Rakovina prsníka59 štúdií
- Rakovina (všetky typy)51 štúdií
- Metastatická rakovina45 štúdií
- Rakovina prostaty45 štúdií
- Rakovina pľúc41 štúdií
- Obézita41 štúdií
- Rakovina vaječníkov36 štúdií
- Kolorektálny karcinóm34 štúdií
- Cievna mozgová príhoda34 štúdií
- Srdcové zlyhanie31 štúdií
- Nadváha29 štúdií
Z ClinicalTrials.gov, dáta načítané 6. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.